AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsTechnology, Industry, AgricultureInformation ScienceHealth Care
DoxorubicinAntibiotics, AntineoplasticChemistry, PharmaceuticalDrug CarriersDrug CompoundingDelayed-Action PreparationsExcipientsLiposomesVincristineAntineoplastic Combined Chemotherapy ProtocolsTabletsRazoxaneCyclophosphamideDrug Delivery SystemsAntineoplastic AgentsDosage FormsPolyethylene GlycolsDrug StabilityParticle SizeTechnology, PharmaceuticalEmulsionsDrug Resistance, NeoplasmNanoparticlesP-GlycoproteinCell Line, TumorTherapeutic EquivalencyCapsulesDose-Response Relationship, DrugPharmaceutical VehiclesPaclitaxelDrug Resistance, MultipleDrug Administration SchedulePrednisoneBiological AvailabilityBreast NeoplasmsSolubilityPowdersEtoposideTreatment OutcomeVinblastinePharmaceutical SolutionsCisplatinNanocapsulesSkin AbsorptionMethylcelluloseDaunorubicinAdministration, OralCell SurvivalDrug SynergismLeukemia P388PoloxamerApoptosisCardiotoxinsHydroxyethylrutosideTumor Cells, CulturedSuspensionsIfosfamideCombined Modality TherapySarcomaDrug ResistanceDrug Screening Assays, AntitumorAnthracyclinesFreeze DryingTime FactorsArea Under CurveBleomycinPolymersAdministration, TopicalInfusions, IntravenousAntineoplastic Agents, PhytogenicProdrugsPolyglycolic AcidMitoxantroneMicellesDrug StorageSurvival AnalysisMethotrexateDisease-Free SurvivalTissue DistributionGelsVerapamilPolymethacrylic AcidsPolysorbatesChitosanSurface-Active AgentsPharmaceutical PreparationsAdministration, CutaneousHeart DiseasesHeartTaxoidsMice, NudeFluorouracilCardiomyopathiesInjections, IntravenousChromatography, High Pressure LiquidOsteosarcomaDrug CombinationsDrug Evaluation, PreclinicalNeoplasmsXenograft Model Antitumor Assays
LiposomesPaclitaxelDoxilMethod and loaded with doxorubicinVincristineCaelyxOvarianLiposomeHydrochlorideAnticancerInjectionVitroChemotherapyAnthracyclinesAntineoplasticTumorCytotoxic effectMammaryChemotherapeuticBreast cancerToxicityCardiacTreatmentCompositionPharmaceuticalNauseaCombinationBindDrugsCancersParametersCellWorkEvaluateSizeProteinsTherapySide effects
Liposomes3
  • Doxorubicin liposomal is a pegylated formulation that protects the liposomes and, thereby, increases blood circulation time. (medscape.com)
  • Liposomes, containing disparate ceramides, were prepared in a molar ratio of 44:40:4:12 mol% of DOTAP/ cholesterol/PEG2000-DSPE/Ceramide, respectively using lipid film hydration method and loaded with doxorubicin (ratio of 0.2:1). (auburn.edu)
  • Liposomes were characterized by measuring size, polydispersity index, release profile and doxorubicin content. (auburn.edu)
Paclitaxel8
Doxil3
  • and Doxil, a pegylated liposomal formulation of doxorubicin. (wikipedia.org)
  • In this study our aim was to evaluate the susceptibility of the pegylated liposomal formulation of doxorubicin (PLD/Doxil(R)/Caelyx(R)) to MDR. (mtak.hu)
  • The generic ingredient in DOXIL (LIPOSOMAL) is doxorubicin hydrochloride . (drugpatentwatch.com)
Method and loaded with doxorubicin1
  • Pluronic F127-Based Cubosomes were prepared by low energy stirring method and loaded with doxorubicin. (ijper.org)
Vincristine5
  • In patients with renal failure or highly aggressive disease, therapy with vincristine, Adriamycin (doxorubicin), and dexamethasone (VAD) may be preferred. (medscape.com)
  • M.S. Webb, N.L. Boman, D. Masin, D. Yapp, E. Ramsay, P.R. Cullis and M.B. Bally, "A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity", Biochim. (ubc.ca)
  • 2006). Therapeutically Optimized Rates of Drug Release can be Achieved by Varying the Drug-to-Lipid Ratio in Liposomal Vincristine Formulations. (ubc.ca)
  • 2005). Preparation, Physical Characterization and Biological Analysis of Liposomal Formulations of Vincristine. (ubc.ca)
  • A 7-month-old girl, who had acute lymphoblastic leuke- genic test came back negative, but the viral culture showed an mia with meningeal involvement (treated with intravenous unidentified cytopathic effect only apparent in LLC-MK2 cells vincristine and doxorubicin, as well as intrathecal methotrex- after 14 days of incubation (isolate 2). (cdc.gov)
Caelyx3
  • Secondly, nanoparticles were loaded with DOX and their in vitro and ex vivo/in vivo delivery was assessed, in comparison with liposomal Doxorubicin (Caelyx). (dovepress.com)
  • SiNPs-TZ (1:8 Hc-TZ) nanoparticles loaded with Doxorubicin (DOX-SiNPs-TZ) showed a similar DOX delivery capability than Caelyx (at 6 h p.i.), in in vitro and ex vivo assays. (dovepress.com)
  • Two liposomal formulations of doxorubicin (Caelyx (R) and Doxopeg (R)) were evaluated for phospholipid content, doxorubicin concentration, liposomal size, zeta potential, osmolarity, phospholipid peroxidation, in vitro release of the drug, pharmacokinetic profile, and cytotoxicity in cancer cell cultures. (dna-pkinhibitors.com)
Ovarian4
  • Industrial Relevance: This study presents an example of the successful integration of a well- known herbal supplement, AHCC, with traditional western medicine cytotoxic agent, pegylated liposomal doxorubicin, for the treatment of recurrent ovarian cancer. (researchgate.net)
  • Strother, R & Matei, D 2009, ' Pegylated liposomal doxorubicin in ovarian cancer ', Therapeutics and Clinical Risk Management , vol. 5, no. 1, pp. 639-650. (northwestern.edu)
  • Doxorubicin is a prescription medication used to treat certain types of cancer in adults and children including breast cancer, lung cancer , and ovarian cancer . (medicap.com)
  • Pegdoxine (Doxorubicin Hydrochloride Pegylated Liposomal) injection is used to treat certain types of cancer (ovarian cancer, AIDs related to Kaposi's sarcoma, and multiple myeloma). (magicinepharma.com)
Liposome5
  • Doxorubicin enriched with C6 and C8-ceramide exhibited the highest cytotoxicity against MDA-MB-231 and PC3 cells compared to liposome formulation that does not contain ceramide and free doxorubicin. (auburn.edu)
  • Furthermore, cellular uptake of liposomal doxorubicin enriched with C6 and C8-ceramide was higher than both free doxorubicin and liposome formulation without ceramide. (auburn.edu)
  • Stealth liposome nanoparticles have been used as an effective strategy for improving drug delivery and limiting systemic toxicity, but can still suffer from inconsistencies in formulation, sub-optimal drug release and poor detection in vivo . (confex.com)
  • These particles are readily taken up even by aggressive, hormone-refractory prostate cancer cells and the data suggest that they possess similar tumor deposition properties in vivo compared to traditional long-circulating sterically stabilized liposome (SSL) formulations. (confex.com)
  • 2008). Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. (ubc.ca)
Hydrochloride4
Anticancer3
  • PLD is an improved formulation of an anticancer drug that has been around since the 1960s. (cochrane.org)
  • Dermos™ is a topical treatment for AIDS-associated Kaposi's sarcoma (AIDS-KS) and other skin cancers as well as proliferative diseases of the skin utilizing a nanosomal formulation of a potent anticancer drug. (aphios.com)
  • The platforms were able to released anticancer drug doxorubicin (DOX) in response to an ambient pH drop from 7.4 to 5.5. (europa.eu)
Injection1
  • When used to deliver anti-cancer medications in our models, the new formulation has a four-fold higher maximum tolerated dose than the same drug by itself, and it induced nearly complete tumor regression after one injection," said Ashutosh Chilkoti, Theo Pilkington Professor of Biomedical Engineering at Duke's Pratt School of Engineering. (rdworldonline.com)
Vitro3
  • In vitro activity of doxorubicin-loaded cubosomes was studied on HCT-116 cells. (ijper.org)
  • We also validated this formulation technologically and tested its behavior in in vitro colorectal cancer (CRC) models, including CRC patient-derived tumor organoids (PDOs). (frontiersin.org)
  • Osmolarity and peroxidation in both formulations was similar and the in vitro drug release assay indicated Quisinostat minimal release (2 %) of the doxorubicin content after 48 h. (dna-pkinhibitors.com)
Chemotherapy3
  • My results showed promise in improving the efficacy of doxorubicin (a chemotherapy drug), inhibition of cancer cell proliferation, and hampering cancer cell migration. (brown.edu)
  • Future experiments look to include anti-cancer drugs in the hydrogel formulation which could be a solution to the harmful side effects of systemic chemotherapy administration. (brown.edu)
  • Treating early-stage KS without systemic chemotherapy eliminates the associated modest myelosuppression and "a theoretical risk for secondary malignancies, as well as cardiotoxicity (although that seems much less common than when nonliposomal formulations are used)," Dr. Bower said. (medscape.com)
Anthracyclines1
Antineoplastic2
  • Doxorubicin a potent antineoplastic agent is widely used but has severe adverse effects. (ijper.org)
  • A topical formulation of an antineoplastic drug that is effective against visual and subcutaneous Kaposi's sarcoma will reduce the systemic use of these drugs, minimizing blood toxicity levels and improving a patient's quality of life. (aphios.com)
Tumor5
  • Here, we merge enhanced drug delivery by nanotechnology with tumor cell membrane modulation combined in a single formulation. (eur.nl)
  • MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) tests demonstrated that the GA-mPEG 2000 micelle formulation had obvious cytotoxicity to tumor cells and human umbilical vein endothelial cells. (dovepress.com)
  • Conjugation of hydrophilic polymers with small molecule drugs to produce polymer-drug conjugate systems has been demonstrated to be a viable formulation strategy for utilizing hydrophobic drugs in a water-soluble manner, which may offer advantages over the corresponding parent drugs, including fewer side effects, improved solubility, passive tumor targeting, an improved pharmacokinetic profile, and lower plasma concentrations. (dovepress.com)
  • The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. (northwestern.edu)
  • The mice treated with doxorubicin alone had an average tumor size 25 times greater than those treated with the new combination. (rdworldonline.com)
Cytotoxic effect2
  • The obtained results show that doxorubicin-loaded cubosomes can be used to increase the cytotoxic effect in CRC cells and can be used with other chemotherapeutic agents. (ijper.org)
  • Enhanced cytotoxic effect was noticed between doxorubicin and both C6 and C8 ceramide in both cell lines. (auburn.edu)
Mammary1
  • Consistent with the higher Pgp levels needed to confer resistance, PLD administration was able to overcome doxorubicin insensitivity of the mouse mammary tumors. (mtak.hu)
Chemotherapeutic1
  • Chemotherapeutic drugs such as doxorubicin are cytotoxic agents that are effective at killing cancer cells, but are also toxic to healthy cells. (confex.com)
Breast cancer3
  • Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. (mtak.hu)
  • Doxorubicin (DOX) is recognized by Pgp and therefore it can induce therapy resistance in breast cancer patients. (mtak.hu)
  • Co-delivery of short chain ceramide, C6-Ceramide (C6-Cer) and C8-Ceramide (C8-Cer) and doxorubicin (DOX) using a liposomal system in MDA-MB-231 breast cancer and PC3 prostate cancer cell lines for synergistic cytotoxic effects was investigated. (auburn.edu)
Toxicity3
  • The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. (northwestern.edu)
  • Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. (northwestern.edu)
  • A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. (northwestern.edu)
Cardiac1
Treatment3
  • Liposomal formulations of daunorubicin and doxorubicin have been approved by the FDA for first-line and second-line systemic treatment of AIDS-KS. (aphios.com)
  • Your periods may or may not return after you complete your treatment of Doxorubicin. (medicap.com)
  • The latest experiments involved doxorubicin, a commonly used agent for the treatment of cancers of the blood, breast, ovaries and other organs. (rdworldonline.com)
Composition1
  • This is achieved through the incorporation of Short chain sphingolipids (SCSs) in the liposomal composition, which permeabilizes cell membranes to amphiphilic drugs such as Doxorubicin (Dxr). (eur.nl)
Pharmaceutical1
  • The optimization of pharmaceutical formulations may represent a daunting challenge since even relatively simple processes can be affected by many variables, each one with its own potential contribution to the results. (frontiersin.org)
Nausea1
Combination2
  • The objective was to define the mechanism of the growth inhibition of active hexose correlated compound (AHCC) alone and evaluate its activity in combination with pegylated liposomal doxorubicin (PLD). (researchgate.net)
  • The researchers injected mice with tumors implanted under their skin with either the chimeric polypeptide-doxorubicin combination or doxorubicin alone. (rdworldonline.com)
Bind1
  • The iron-doxorubicin complex can bind DNA and cell membranes, producing free hydroxyl (OH) radicals that cleave DNA and cell membranes. (magicinepharma.com)
Drugs1
  • The information obtained within these methods will lead to better understanding of formulations, designed for peptide, DNA and anti-cancer drugs delivery. (europa.eu)
Cancers1
  • The Dermos™ formulation with other active ingredients will find utility in melanoma, other types of skin cancers and proliferative diseases of the skin such as alopecia. (aphios.com)
Parameters1
  • However, these studies did not elucidate the critical experimental parameters involved in leukosomes formulation. (frontiersin.org)
Cell3
  • We show that cells selected to be resistant to DOX are cross-resistant to PLD and PLD is also ineffective in an allograft model of doxorubicin-resistant mouse B-cell leukemia. (mtak.hu)
  • In contrast, KS Y-1 cells treated with the topical formulation exhibited overall induced reduction in cell size as well as diffuse staining and clumping of chromatin which is consistent with apoptosis. (aphios.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
Work1
Evaluate1
Size1
  • The prepared cubosomes have the required nano-size and the FTIR results showed the presence of both doxorubicin and Pluronic F-127. (ijper.org)
Proteins1
  • When targeting cancer cells, both animal and plant proteins may be used in a formulation process to create self-assembled viruses and platforms that can successfully eradicate metastatic cancer cells. (benthamscience.com)
Therapy1
Side effects3